Department of Pharmaceutics, SVKM'S Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, Maharashtra, India.
Department of Pharmacology, SVKM'S Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, Maharashtra, India.
Indian J Pharmacol. 2021 May-Jun;53(3):221-225. doi: 10.4103/ijp.IJP_68_20.
Copper is an important element essential for metabolism and normal human body function. Although it is an essential element, related imbalance leads to toxic effects. Studies have proved that there is an increase in copper level in cancer cells. Evidences suggest the link between increase in copper levels and progression of various types of cancers. Different strategies have been utilized to decrease the level of copper in various types of cancer cells. However, it was observed that cell machinery involved in copper homeostasis plays critical factor in lowering copper levels in cancer cells. The outcomes of many monotherapies consisting copper-lowering agents for the treatment of different types of cancers showed that the inhibition of single factor is not sufficient to inhibit the growth of cancer cells. The combination of copper-lowering agent with chemotherapeutic agent showed synergistic effect. Interestingly, the presence of copper-lowering agent in such combinations significantly improved the efficacy of chemotherapeutic agent. The present work has focused on the discussion of outcomes of studies involving anti-copper agent and chemotherapeutic agent and related future strategies.
铜是新陈代谢和人体正常功能所必需的重要元素。尽管它是一种必需元素,但相关的失衡会导致毒性作用。研究已经证明癌细胞内铜水平升高。有证据表明,铜水平的升高与各种类型癌症的进展有关。已经利用了不同的策略来降低各种类型癌细胞中的铜水平。然而,观察到参与铜稳态的细胞机制在降低癌细胞中的铜水平方面起着关键作用。许多包含降低铜水平的药物的单一疗法的结果表明,抑制单一因素不足以抑制癌细胞的生长。降低铜剂与化疗药物的联合使用显示出协同作用。有趣的是,在这些组合中加入降低铜剂可显著提高化疗药物的疗效。目前的工作重点是讨论涉及抗铜剂和化疗药物的研究结果及相关的未来策略。